NO20062082L - Pellets inneholdende venlafaksinhydroklorid - Google Patents
Pellets inneholdende venlafaksinhydrokloridInfo
- Publication number
- NO20062082L NO20062082L NO20062082A NO20062082A NO20062082L NO 20062082 L NO20062082 L NO 20062082L NO 20062082 A NO20062082 A NO 20062082A NO 20062082 A NO20062082 A NO 20062082A NO 20062082 L NO20062082 L NO 20062082L
- Authority
- NO
- Norway
- Prior art keywords
- venlafaxine hydrochloride
- pellets
- pellets containing
- weight
- containing venlafaxine
- Prior art date
Links
- 239000008188 pellet Substances 0.000 title abstract 4
- 229960002416 venlafaxine hydrochloride Drugs 0.000 title abstract 3
- QYRYFNHXARDNFZ-UHFFFAOYSA-N venlafaxine hydrochloride Chemical compound [H+].[Cl-].C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 QYRYFNHXARDNFZ-UHFFFAOYSA-N 0.000 title abstract 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000001103 potassium chloride Substances 0.000 abstract 1
- 235000011164 potassium chloride Nutrition 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0303382A HUP0303382A2 (hu) | 2003-10-10 | 2003-10-10 | Venlafaxin-hidroklorid-tartalmú pelletek |
PCT/HU2004/000095 WO2005034930A1 (en) | 2003-10-10 | 2004-10-08 | Pellets containing venlafaxine hydrochloride |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20062082L true NO20062082L (no) | 2006-05-09 |
Family
ID=90001704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20062082A NO20062082L (no) | 2003-10-10 | 2006-05-09 | Pellets inneholdende venlafaksinhydroklorid |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP1677777B1 (el) |
CN (1) | CN1882321B (el) |
AT (1) | ATE359771T1 (el) |
AU (1) | AU2004280132B2 (el) |
BG (1) | BG109539A (el) |
CY (1) | CY1106693T1 (el) |
CZ (1) | CZ2006269A3 (el) |
DE (1) | DE602004006009T2 (el) |
DK (1) | DK1677777T3 (el) |
EA (1) | EA009695B1 (el) |
ES (1) | ES2285538T3 (el) |
HK (1) | HK1098364A1 (el) |
HR (2) | HRP20060136A2 (el) |
HU (1) | HUP0303382A2 (el) |
IL (1) | IL174830A (el) |
NO (1) | NO20062082L (el) |
PL (2) | PL1677777T3 (el) |
PT (1) | PT1677777E (el) |
RS (2) | RS20060252A (el) |
SI (1) | SI1677777T1 (el) |
SK (1) | SK50442006A3 (el) |
UA (1) | UA82268C2 (el) |
WO (1) | WO2005034930A1 (el) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130010512A (ko) | 1999-10-29 | 2013-01-28 | 유로-셀티크 소시에떼 아노뉨 | 서방성 하이드로코돈 제형 |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
KR100960200B1 (ko) | 2000-10-30 | 2010-05-27 | 유로-셀티크 소시에떼 아노뉨 | 서방성 하이드로코돈 제형 |
IL146462A (en) | 2001-11-13 | 2015-02-26 | Lycored Bio Ltd | Prolonged-release preparations containing as an active compound and analapaxin hydrochloride |
US20080193524A1 (en) * | 2005-07-28 | 2008-08-14 | Dr. Reddy's Laboratories Ltd. | Extended Release Venlafaxine Compositions |
WO2007135470A1 (en) * | 2006-05-19 | 2007-11-29 | EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság | Process for the preparation and surface coating of pellets |
US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
JP2013526523A (ja) | 2010-05-11 | 2013-06-24 | シマ ラブス インク. | メトプロロールを含むアルコール耐性持続放出性経口剤形 |
JP2013526522A (ja) * | 2010-05-11 | 2013-06-24 | シマ ラブス インク. | ベンラファキシンを含むアルコール耐性持続放出性剤形 |
US20160367502A1 (en) * | 2012-12-19 | 2016-12-22 | Ratiopharm Gmbh | Film coated pellets |
CN103893151B (zh) * | 2012-12-31 | 2018-04-27 | 石药集团中奇制药技术(石家庄)有限公司 | 一种盐酸文拉法辛缓释胶囊及其制备方法 |
WO2015065547A1 (en) | 2013-10-31 | 2015-05-07 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
EP3965733A4 (en) | 2019-05-07 | 2023-01-11 | Clexio Biosciences Ltd. | ABUSE DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE |
US20220062200A1 (en) | 2019-05-07 | 2022-03-03 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
CN114028577B (zh) * | 2021-10-20 | 2024-07-02 | 珠海市东辰制药有限公司 | 一种二氧化硅丸芯及其制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE57198A1 (es) * | 1996-03-25 | 1998-10-10 | American Home Prod | Formula de liberacion prolongada |
EP1331003B1 (en) * | 1996-03-25 | 2015-08-26 | Wyeth LLC | Extended release formulation containing venlafaxine |
UA77145C2 (en) * | 1997-11-05 | 2006-11-15 | Wyeth Corp | Extended release dosage formulation |
CN1334080A (zh) * | 2001-07-25 | 2002-02-06 | 成都康弘制药有限公司 | 盐酸万拉法新缓释片及其制备方法 |
IL146462A (en) * | 2001-11-13 | 2015-02-26 | Lycored Bio Ltd | Prolonged-release preparations containing as an active compound and analapaxin hydrochloride |
AR039162A1 (es) * | 2002-03-28 | 2005-02-09 | Synthon Bv | Formulaciones de venlafaxina de liberacion extendida |
-
2003
- 2003-10-10 HU HU0303382A patent/HUP0303382A2/hu unknown
-
2004
- 2004-08-10 UA UAA200605099A patent/UA82268C2/uk unknown
- 2004-10-08 ES ES04791654T patent/ES2285538T3/es not_active Expired - Lifetime
- 2004-10-08 RS YUP-2006/0252A patent/RS20060252A/sr unknown
- 2004-10-08 EA EA200600675A patent/EA009695B1/ru not_active IP Right Cessation
- 2004-10-08 EP EP04791654A patent/EP1677777B1/en not_active Expired - Lifetime
- 2004-10-08 AU AU2004280132A patent/AU2004280132B2/en not_active Ceased
- 2004-10-08 RS RS20060252A patent/RS52150B/en unknown
- 2004-10-08 PL PL04791654T patent/PL1677777T3/pl unknown
- 2004-10-08 SK SK5044-2006A patent/SK50442006A3/sk unknown
- 2004-10-08 CZ CZ20060269A patent/CZ2006269A3/cs unknown
- 2004-10-08 DK DK04791654T patent/DK1677777T3/da active
- 2004-10-08 CN CN2004800330326A patent/CN1882321B/zh not_active Expired - Fee Related
- 2004-10-08 AT AT04791654T patent/ATE359771T1/de active
- 2004-10-08 PT PT04791654T patent/PT1677777E/pt unknown
- 2004-10-08 WO PCT/HU2004/000095 patent/WO2005034930A1/en active IP Right Grant
- 2004-10-08 PL PL379541A patent/PL379541A1/pl not_active IP Right Cessation
- 2004-10-08 SI SI200430364T patent/SI1677777T1/sl unknown
- 2004-10-08 DE DE602004006009T patent/DE602004006009T2/de not_active Expired - Lifetime
-
2006
- 2006-04-06 IL IL174830A patent/IL174830A/en not_active IP Right Cessation
- 2006-04-07 HR HR20060136A patent/HRP20060136A2/xx not_active Application Discontinuation
- 2006-05-09 NO NO20062082A patent/NO20062082L/no unknown
- 2006-05-10 BG BG109539A patent/BG109539A/bg unknown
-
2007
- 2007-05-04 HK HK07104778.3A patent/HK1098364A1/xx not_active IP Right Cessation
- 2007-07-02 CY CY20071100874T patent/CY1106693T1/el unknown
- 2007-07-16 HR HR20070322T patent/HRP20070322T3/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP1677777B1 (en) | 2007-04-18 |
ATE359771T1 (de) | 2007-05-15 |
CY1106693T1 (el) | 2012-05-23 |
HUP0303382A2 (hu) | 2005-08-29 |
HRP20070322T3 (en) | 2007-09-30 |
HRP20060136A2 (en) | 2006-06-30 |
CN1882321A (zh) | 2006-12-20 |
DK1677777T3 (da) | 2007-09-03 |
DE602004006009T2 (de) | 2008-01-10 |
HK1098364A1 (en) | 2007-07-20 |
UA82268C2 (uk) | 2008-03-25 |
AU2004280132B2 (en) | 2009-10-22 |
BG109539A (bg) | 2006-11-30 |
SI1677777T1 (sl) | 2007-10-31 |
PT1677777E (pt) | 2007-06-21 |
IL174830A0 (en) | 2008-04-13 |
ES2285538T3 (es) | 2007-11-16 |
CN1882321B (zh) | 2011-06-08 |
PL379541A1 (pl) | 2006-10-02 |
AU2004280132A1 (en) | 2005-04-21 |
DE602004006009D1 (de) | 2007-05-31 |
IL174830A (en) | 2010-04-15 |
RS52150B (en) | 2012-08-31 |
EA009695B1 (ru) | 2008-02-28 |
WO2005034930A1 (en) | 2005-04-21 |
CZ2006269A3 (cs) | 2006-07-12 |
HUP0303382D0 (en) | 2003-12-29 |
EP1677777A1 (en) | 2006-07-12 |
RS20060252A (en) | 2008-08-07 |
EA200600675A1 (ru) | 2006-08-25 |
SK50442006A3 (sk) | 2006-08-03 |
PL1677777T3 (pl) | 2007-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20062082L (no) | Pellets inneholdende venlafaksinhydroklorid | |
HRP20171518T1 (hr) | Tabletni pripravak bez prouzrokovanja kvarova kod tabletiranja | |
NO20053681L (no) | Dispersjon av smaksmaskerte krystaller eller granuler av aktive forbindelser, tyggbare blote kapsler fylt med nevnte dispersjon og fremgangsmate for fremstilling derav | |
JP2018513852A5 (el) | ||
RU2005115855A (ru) | Композиция трамадола продлонгированного высвобождением с 24-часовым действием | |
EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
HRP20192026T4 (hr) | Formulacija tableta od neratinib maleata | |
BR112018011777A2 (pt) | composições de fenfluramina e métodos para o preparo das mesmas | |
NO20045072L (no) | Tablett med hoyt medikamentinnhold | |
NO341573B1 (no) | Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen | |
JO2973B1 (en) | Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol | |
MX2010003923A (es) | Formulacion farmaceutica de valsartan. | |
MY139086A (en) | Use of debranched starch in extrusion-spheronization pharmaceutical pellets | |
NO20092662L (no) | Sammensetning med forlenget frigjoring og fremgangsmate for a produsere det samme | |
MX2020005942A (es) | Delgada pelicula oral con alta carga de agente activo. | |
MX2010007672A (es) | Composicion estabilizada de liberacion sostenida de clorhidrato de bupropion y proceso para su preparacion. | |
GEP20043285B (en) | Sustained Release Beadlets Containing Stavudine, Method for Their Production, Pharmaceutical Composition Containing the Same and Use Thereof for Treatment Retroviral Infections | |
ATE329581T1 (de) | Pharmazeutische formulierung, die n-((1-n-butyl-4-piperidinyl)menthyl)-3,4-dihydr -2h-(1, 3)oxazino(3,2-a)indol-10-carboxamid oder ein entsprechendes salz hiervon enthält, sowie deren herstellungsprozess, welcher trockengranulierung beinhaltet | |
HRP20100120T1 (hr) | Formulacije s valsartanom | |
WO2007123883A3 (en) | Oral dosage formulations and methods of preparing the same | |
JP2011516544A5 (el) | ||
KR20080075113A (ko) | 에스시탈로프람 및 부프로피온을 함유하는 안정한 약학적제형 | |
WO2006087358A3 (en) | Composition for adjusting water quality for administration of water sanitizer sensitive medicaments or vaccines | |
NO20073850L (no) | Farmasoytisk polymersammensetning for oral kontrollert frigivelsesavlevering av terbutalinsulfat | |
EA200900249A1 (ru) | Фармацевтическая композиция и способ ее получения |